10-Q: Zynex Reports 10% Revenue Increase in First Quarter, Device Orders Surge 23%

Zynex, Inc. announced a 10% increase in net revenue for the first quarter of 2024, driven by a significant 23% rise in device orders compared to the same period last year.

Summary

• Zynex, Inc. reported a 10% increase in net revenue, reaching $46.5 million for the first quarter of 2024, compared to $42.2 million in the same period of 2023.
• The company experienced a 23% increase in device orders during the first quarter of 2024 compared to the first quarter of 2023.
• Net income for the quarter was $10,000, a decrease from $1.6 million in the first quarter of 2023.
• Cash provided by operating activities was $2.1 million, slightly up from $1.9 million in the same period last year.
• Working capital decreased to $56.2 million as of March 31, 2024, from $69.3 million at the end of 2023.
• Device revenue increased by 17% to $14.0 million, while supplies revenue grew by 8% to $32.5 million.
• Cost of revenue remained flat at $9.3 million, but decreased as a percentage of revenue to 20% from 22% year-over-year.
• Sales and marketing expenses increased by 10% to $23.4 million, while general and administrative expenses rose by 17% to $13.3 million.

Sentiment

Score: 5

Explanation: The document presents mixed results. While revenue growth and device order increases are positive, the significant decrease in net income and the identified material weakness in internal controls are concerning. The company's share repurchase programs indicate confidence, but the overall sentiment is neutral to slightly negative due to the profitability issues.

Positives

• The company experienced a significant 23% increase in device orders, indicating strong demand for its products.
• Net revenue increased by 10%, demonstrating solid growth in the company's sales.
• Cost of revenue as a percentage of revenue decreased, suggesting improved efficiency in production and supply chain management.
• Cash provided by operating activities increased slightly, indicating a healthy cash flow from core business operations.
• The company completed a $10.4 million share repurchase program and initiated a new $20 million share repurchase program, demonstrating confidence in the company's future prospects.

Negatives

• Net income decreased significantly to $10,000 from $1.6 million in the same quarter of the previous year.
• Working capital decreased from $69.3 million to $56.2 million.
• General and administrative expenses increased by 17%, outpacing revenue growth.
• Sales and marketing expenses increased by 10%, impacting overall profitability.

Risks

• The company's financial statements have a material weakness in internal control over financial reporting related to IT systems and accounts receivable valuation.
• The company relies on a limited number of suppliers for its electrotherapy products, which could pose a risk if those suppliers experience disruptions.
• The company is subject to the risk of refund requests from insurance providers, which can impact revenue.
• The company's forecasting model to estimate collections could change, which could have an impact on the company's results of operations and cash flows.
• Changes in the company's third-party payer mix could affect net revenue and related receivables.

Future Outlook

The company believes its cash and cash equivalents, along with anticipated cash flow from operations, will be sufficient to meet its working capital and capital expenditure requirements for at least the next twelve months.

Management Comments

• Management is committed to maintaining a strong internal control environment.
• Management will take comprehensive actions to remediate the material weakness in internal control over financial reporting.

Industry Context

The medical device industry is subject to regulatory approvals and reimbursement challenges, which can impact revenue and profitability. Zynex's focus on non-invasive pain management aligns with a growing trend towards reducing reliance on medications. The company's growth in device orders and supplies revenue indicates a positive market reception for its products.

Comparison to Industry Standards

• Zynex's 10% revenue growth is a positive sign, but the decrease in net income is a concern compared to industry peers.
• Companies like Nevro Corp and Insulet Corp, which also operate in the medical device space, have reported varying results, with some showing higher revenue growth but also facing challenges in profitability.
• Zynex's focus on direct sales and recurring supply revenue is similar to some competitors, but the company's reliance on third-party payers for reimbursement creates unique challenges.
• The material weakness in internal control over financial reporting is a significant issue that needs to be addressed to meet industry standards for financial reporting.

Related Party Transactions

• The company purchased 300,000 shares of common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on May 10, 2023 of $9.61 per share for $2.9 million.
• The company purchased 300,000 shares of the company's common stock from Thomas Sandgaard, Chairman, President, Chief Executive Officer and Principal Executive Officer, at the closing market price on June 13, 2023, of $8.62 per share for $2.6 million.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and the material weakness in internal controls.
• Employees may be affected by the company's efforts to remediate the internal control issues.
• Customers may benefit from the company's continued growth and product development.
• Suppliers may be impacted by the company's efforts to diversify its supply chain.
• Creditors may be concerned about the company's decreased working capital.

Next Steps

• The company will continue to monitor the impact of COVID-19 on its operations.
• The company will implement remediation plans to address the material weakness in internal control over financial reporting.
• The company will continue to execute its share repurchase program.

Key Dates

Keywords

medical devices, electrotherapy, pain management, revenue, device orders, supplies, financial results, share repurchase, internal control, healthcare